BR0309740A - Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos - Google Patents
Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmosInfo
- Publication number
- BR0309740A BR0309740A BR0309740-4A BR0309740A BR0309740A BR 0309740 A BR0309740 A BR 0309740A BR 0309740 A BR0309740 A BR 0309740A BR 0309740 A BR0309740 A BR 0309740A
- Authority
- BR
- Brazil
- Prior art keywords
- epa
- dha
- acid
- derivative
- mixture
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title abstract 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 title abstract 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract 5
- 239000002253 acid Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 230000006931 brain damage Effects 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE áCIDO EICOSAPENTAENóICO (EPA), áCIDO DOCOSAEXAENóICO (DHA) OU DE UMA MISTURA DE EPA E DHA OU DE UM SAL OU DERIVADO FARMACEUTICAMENTE ACEITáVEIS DOS MESMOS". A invenção está direcionada ao uso do n-3 PUFA EPA e/ou DRA na preparação de um medicamento oral para prevenir dano cerebral em pacientes tendo sintomas de aterosclerose de artérias que abastecem o cérebro.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0210212.7A GB0210212D0 (en) | 2002-05-03 | 2002-05-03 | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
GB0307625A GB2388026B (en) | 2002-05-03 | 2003-04-02 | Use of epa and dha in secondary prevention of neurological events,particulary strokes |
PCT/GB2003/001945 WO2003092673A1 (en) | 2002-05-03 | 2003-05-02 | Use of epa and dha in secondary prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0309740A true BR0309740A (pt) | 2005-02-22 |
Family
ID=29404296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0309740-4A BR0309740A (pt) | 2002-05-03 | 2003-05-02 | Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1501493B1 (pt) |
CN (1) | CN1665496B (pt) |
AU (1) | AU2003229993B2 (pt) |
BR (1) | BR0309740A (pt) |
CA (1) | CA2485116C (pt) |
IL (1) | IL164984A0 (pt) |
NO (1) | NO334959B1 (pt) |
NZ (1) | NZ548508A (pt) |
WO (1) | WO2003092673A1 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
US7550613B2 (en) | 2005-05-04 | 2009-06-23 | Pronova Biopharma Norge As | Compounds |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
CA2571462C (en) * | 2006-02-07 | 2013-08-13 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing recurrence of stroke |
CN101049297B (zh) * | 2006-04-06 | 2010-11-24 | 北京百慧生化制药有限责任公司 | 一种高dha型-乙酯和epa-乙酯的脂肪酸乙酯及其制造方法和制剂 |
BRPI0717883A2 (pt) | 2006-11-01 | 2013-10-29 | Pronova Biopharma Norge As | Compostos lipídicos, composição contendo os mesmos e uso dos referidos compostos |
JP5552313B2 (ja) | 2006-11-01 | 2014-07-16 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物 |
BRPI0718393A2 (pt) * | 2006-11-03 | 2013-11-26 | Pronova Biopharma Norge As | Álcoois de ácido graxo |
EP3593797A1 (en) | 2006-12-28 | 2020-01-15 | Suntory Holdings Limited | Nerve-regenerating agent |
AU2009315314B2 (en) * | 2008-11-14 | 2013-04-18 | Bomi P. Framroze | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis |
BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
KR102354949B1 (ko) * | 2009-10-23 | 2022-01-24 | 바스프 에이에스 | 지방산 오일 혼합물의 코팅된 캡슐 및 정제 |
US20110178105A1 (en) * | 2010-01-15 | 2011-07-21 | E.I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
TW201334808A (zh) * | 2012-02-29 | 2013-09-01 | Braun Melsungen Ag | 含有荷爾蒙之包含磷蝦磷脂質的乳劑 |
EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20140249225A1 (en) * | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) * | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
CN113884586A (zh) * | 2021-06-17 | 2022-01-04 | 上海市肺科医院 | 一种特发性肺动脉高压的预后标记物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU210122B (en) * | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
IT1308613B1 (it) | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
-
2003
- 2003-05-02 AU AU2003229993A patent/AU2003229993B2/en not_active Ceased
- 2003-05-02 EP EP03722833A patent/EP1501493B1/en not_active Revoked
- 2003-05-02 NZ NZ548508A patent/NZ548508A/en not_active IP Right Cessation
- 2003-05-02 BR BR0309740-4A patent/BR0309740A/pt not_active IP Right Cessation
- 2003-05-02 CN CN03815692XA patent/CN1665496B/zh not_active Expired - Fee Related
- 2003-05-02 WO PCT/GB2003/001945 patent/WO2003092673A1/en active Application Filing
- 2003-05-02 CA CA2485116A patent/CA2485116C/en not_active Expired - Fee Related
-
2004
- 2004-11-02 IL IL16498404A patent/IL164984A0/xx unknown
- 2004-12-01 NO NO20045275A patent/NO334959B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1665496B (zh) | 2010-05-05 |
AU2003229993B2 (en) | 2008-07-24 |
CA2485116C (en) | 2013-02-05 |
NO334959B1 (no) | 2014-08-04 |
WO2003092673A1 (en) | 2003-11-13 |
CN1665496A (zh) | 2005-09-07 |
CA2485116A1 (en) | 2003-11-13 |
AU2003229993A1 (en) | 2003-11-17 |
NZ548508A (en) | 2008-04-30 |
NO20045275L (no) | 2005-01-31 |
EP1501493B1 (en) | 2009-10-07 |
IL164984A0 (en) | 2005-12-18 |
EP1501493A1 (en) | 2005-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0309740A (pt) | Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos | |
US5116871A (en) | Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis | |
EP0440341B1 (en) | EFA compositions and therapy | |
PT1152755E (pt) | Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares | |
BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
TW429145B (en) | Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA | |
KR920000324A (ko) | 필수 지방산 처리법 | |
BR0111186A (pt) | Uso de composição de celecoxib para rápido alìvio de dor | |
CA2238465A1 (fr) | Composes triaromatiques, compositions les contenant et utilisations | |
CA1310911C (en) | Essential fatty acid compositions | |
BR9813811A (pt) | "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo" | |
BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
DE3669106D1 (de) | Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe. | |
CA2073913A1 (en) | Preparation of fatty acid medicaments | |
CA2218766A1 (fr) | Composes bicycliques-aromatiques | |
MX9304503A (es) | Compuestos antiinflamatorios. | |
Klawans et al. | Neuroleptic-induced tardive dyskinesias in nonpsychotic patients | |
CA2334843A1 (fr) | Composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie | |
DE60329588D1 (de) | Verwendung von epa and dha zur sekundären prevention von schlaganfällen | |
DK619484A (da) | Farmaceutisk praeparat mod rheumatiske lidelser | |
BR0306778A (pt) | Derivados de carboxamidina e seu uso no tratamento de doenças vasculares | |
CO5580773A2 (es) | Rosuvastatina en estados pre dementes | |
BR0212744A (pt) | Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas | |
EA200100662A1 (ru) | Способ и композиция для поддержания и восстановления целостности кишки | |
ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |